GSK has today filed a declaratory judgment action seeking a declaration that the US Patent 6,331,415 (the "Cabilly" patent) is invalid, unenforceable and not infringed by Arzerra. COPENHAGEN, Denmark, Oct. 8, 2009 –(HSMN NewsFeed) — Genmab A…
Biopharmaceuticals, Litigation
Genmab, GlaxoSmithKline, Genentech, Arzerra, ofatumumab

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Declaratory Judgment Action Filed by GSK”
Leave a Comment